Kishimoto T, Okada K
Gan To Kagaku Ryoho. 1987 Apr;14(4):1051-6.
Twenty patients with lung cancer were treated with a streptococcal preparation, OK-432 in addition to various other treatments, and we evaluated the effect of OK-432 in comparison with an equivalent number of patients without OK-432. With regard to advanced-stage patients, the median survival time of those treated with OK-432 was longer than that of patients without OK-432. Patients whose PPD or SU-PS skin reactions were positive had a longer survival time than those giving a negative reaction. OK-432 significantly increased the reactions for both PPD and SU-PS. On the other hand, OK-432 did not have any significant effect in increasing the numbers of peripheral lymphocytes and T-cell subsets. Furthermore, there were no effects on tumor markers, such as CEA, beta 2-microglobulin and ferritin. However, OK-432 had a remarkable effect in decreasing immunosuppressive acidic protein.
20例肺癌患者在接受各种其他治疗的同时，加用链球菌制剂OK-432进行治疗，我们将使用OK-432治疗的患者与同等数量未使用OK-432的患者进行比较，评估OK-432的疗效。对于晚期患者，接受OK-432治疗者的中位生存时间长于未使用OK-432的患者。PPD或SU-PS皮肤反应呈阳性的患者比呈阴性反应的患者生存时间更长。OK-432可显著增强PPD和SU-PS反应。另一方面，OK-432在增加外周淋巴细胞和T细胞亚群数量方面没有任何显著作用。此外，对癌胚抗原、β2-微球蛋白和铁蛋白等肿瘤标志物也没有影响。然而，OK-432在降低免疫抑制酸性蛋白方面有显著作用。
